27 related articles for article (PubMed ID: 38448403)
1. First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial.
Tian XP; Cai J; Xia Y; Zhang YC; Wang L; Liu PP; Huang HQ; Li YJ; Zhou H; Li ZM; Yang J; Wei LQ; Zou QH; Huang Y; Li J; Ling L; Zhong WL; Cai QQ
Lancet Haematol; 2024 May; 11(5):e336-e344. PubMed ID: 38554717
[TBL] [Abstract][Full Text] [Related]
2. Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma.
Cai J; Liu P; Huang H; Li Y; Ma S; Zhou H; Tian X; Zhang Y; Gao Y; Xia Y; Zhang X; Yang H; Li L; Cai Q
Signal Transduct Target Ther; 2020 Dec; 5(1):289. PubMed ID: 33376237
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of sintilimab, anlotinib, and pegaspargase sandwiched with radiotherapy as first-line therapy in patients with newly diagnosed, stage I-II extranodal natural-killer/T-cell lymphoma.
Sun P; Li Y; Li C; Ren K; Wang Y; Yang H; Jiang W; Zou L; Yang H; Zhou H; Li ZM
Am J Hematol; 2023 Jul; 98(7):1043-1051. PubMed ID: 36970971
[TBL] [Abstract][Full Text] [Related]
4. Sustained remission of multi-line relapsed extranodal NK/T-cell lymphoma, nasal type, following sintilimab and chidamide: A case report.
Xu J; Xu X; Chen J; Wang J; Jiang C; Lv C; Chen B
Medicine (Baltimore); 2021 Mar; 100(10):e24824. PubMed ID: 33725836
[TBL] [Abstract][Full Text] [Related]
5. Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study.
Wei C; Cao X; Zhang W; Zhang Y; Wang W; Zhang L; Yang C; Feng J; Cai H; Chen M; Mao Y; Zhou D
Ann Hematol; 2020 Dec; 99(12):2801-2809. PubMed ID: 32399707
[TBL] [Abstract][Full Text] [Related]
6. Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma.
Xiong J; Cheng S; Gao X; Yu SH; Dai YT; Huang XY; Zhong HJ; Wang CF; Yi HM; Zhang H; Cao WG; Li R; Tang W; Zhao Y; Xu PP; Wang L; Zhao WL
Signal Transduct Target Ther; 2024 Mar; 9(1):62. PubMed ID: 38448403
[TBL] [Abstract][Full Text] [Related]
7. Sintilimab combined with chidamide in the treatment of extranodal nature killer/T-cell lymphoma with secondary hemophagocytic lymphohistiocytosis: Two case reports and literature review.
Xu QY; Yang HY; Li MW; He ZD; Hong HY; Peng ZG
Medicine (Baltimore); 2022 Sep; 101(38):e30731. PubMed ID: 36197207
[TBL] [Abstract][Full Text] [Related]
8. Toxic epidermal necrolysis associated with chemoimmunotherapy for lymphoma: case report and literature review.
Yang W; Xu X; Xia D; Wang H; Jiang J; Yang G
Immunotherapy; 2022 Apr; 14(5):275-282. PubMed ID: 35128931
[TBL] [Abstract][Full Text] [Related]
9. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
10. Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.
Heo YA; Syed YY; Keam SJ
Drugs; 2019 May; 79(7):767-777. PubMed ID: 31030380
[TBL] [Abstract][Full Text] [Related]
11. Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.
Zhang L; Qian Y; Li J; Cui C; Chen L; Qu S; Lu S
Future Oncol; 2022 May; 18(15):1896-1905. PubMed ID: 35311347
[TBL] [Abstract][Full Text] [Related]
12. Advances and challenges of immunotherapies in NK/T cell lymphomas.
He L; Chen N; Dai L; Peng X
iScience; 2023 Nov; 26(11):108192. PubMed ID: 38026157
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]